D. Noterman
Université libre de Bruxelles
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by D. Noterman.
American Journal of Surgery | 2009
Isabelle Veys; Virginie Durbecq; Samira Majjaj; Jean Schobbens; D. Noterman; Nicolas Sirtaine; Maria Dolores Martin Martinez; Dina Hertens; Francesco Feoli; Pierre Bourgeois; Jean-Marie Nogaret; Denis Larsimont
BACKGROUND The accuracy of a molecular reverse transcriptase-polymerase chain reaction (RT-PCR)-based assay for metastases detection in axillary sentinel lymph nodes (SLNs) has recently been validated in our institution and adopted as an intraoperative test for breast cancer patient management. METHODS Molecular assay performance was compared to standard postoperative histology in 253 consecutive patients with clinically node-negative T1 early breast cancer (<2 cm). RESULTS The molecular assay correctly identified 26/27 macrometastases and 11/15 micrometastases. Overall concordance with histopathology was 93%, with 87% sensitivity, 94% specificity, and 75% positive and 97% negative predictive values. The molecular assay was positive in 13/14 patients with SLNs and nonsentinel lymph node (axillary lymph node [ALN])-positive histology. Notably, 2/12 patients with assay-positive/histology-negative SLNs exhibited ALN positivity. CONCLUSIONS This molecular assay can raise the standard of care for patient management as its accuracy is similar to that of standard postoperative histology with the advantage of being standardized, objective, and fast enough for intraoperative use.
Acta Chirurgica Belgica | 2010
Gabriel Liberale; Ph. Lemaitre; D. Noterman; C. Moerman; F. de Neubourg; N. Sirtaine; I. El Nakadi
Abstract Appendicular mucocele (AM) usually denotes a dilatation of the appendiceal lumen as a result of mucus accumulation that may be related to various neoplastic and non-neoplastic processes. Most of them are discovered incidentally. Treatment consists in complete resection avoiding rupture of the cyst in the peritoneal cavity. Indeed, rupture of such a cystic lesion in the peritoneal cavity can induce a catastrophic complication such as ‘pseudomyxoma peritonei’(PMP). Therefore, some authors recommend an open surgical treatment. Currently, the debate concerning the best surgical technique to adopt for AM remains controversial. We report a case of AM found incidentally and treated by laparoscopy. The macroscopic aspect of the appendix suggested the diagnosis intra-operatively and every effort was made to avoid cystic rupture during appendicular resection. The histopathological diagnosis was mucinous cystadeno-ma. The patient is doing well at 2-year follow-up. The reported case and literature review show us that AM is not a contra-indication for laparoscopic surgery, but major concern resides in the early recognition of such a lesion at laparoscopy and in taking appropriate precautionary measures to avoid rupture in the peritoneal cavity.
Breast Journal | 2011
Arnaud Toussaint; Jean-Marie Nogaret; Isabelle Veys; Dina Hertens; D. Noterman; Filip De Neubourg; Denis Larsimont; Pierre Bourgeois
Abstract: Sentinel lymph node biopsy (SLNB) has almost completely replaced complete axillary lymph node dissection (CALND) as the first‐line axillary procedure for clinically node‐negative early stage breast cancer. We assessed the incidence of axillary relapse in patients with negative SLNB who had no additional CALND (group 1, n = 481) and in patients whose SLNB contained micrometastases and had no further CALND (group 2, n = 45). All patients were operated on between November 1997 and December 2005 and followed at the Jules Bordet Institute. The median follow‐up was 48 months. A mean of 2.2 sentinel lymph nodes was removed per patient. Axillary relapse was observed in only one patient (0.2%) in group 1 and in none of the patients in group 2. This study confirms that the axillary recurrence rate after long‐term follow‐up of patients with a negative sentinel lymph node is very rare, provided that the selection criteria are judicious.
PLOS ONE | 2018
Isabelle Veys; Catalin-Florin Pop; Romain Barbieux; Michel Moreau; D. Noterman; Filip De Neubourg; Jean-Marie Nogaret; Gabriel Liberale; Denis Larsimont; Pierre Bourgeois
Background Response to neoadjuvant chemotherapy (NACT), particularly pathologic complete response (pCR), is an independent predictor of favorable clinical outcome in breast cancer (BC). The accuracy of residual disease measurement and reporting is of critical importance in treatment planning and prognosis for these patients. Currently, gross pathological evaluation of the residual tumor bed is the greatest determinant for accurate reporting of NACT response. Fluorescence imaging (FI) is a new technology that is being evaluated for use in the detection of tumors in different oncological conditions. Objective The aim of this study was to evaluate whether indocyanine green fluorescence imaging (ICG-FI) is able to detect residual breast tumor tissue after NACT in breast surgical operative specimens. Methods Patients who underwent NACT for BC and were admitted for breast surgery were selected for participation in this study. Free ICG (0.25 mg/kg) was injected intraoperatively. Tumor-to-background fluorescence ratio (TBFR) was calculated on ex vivo samples from the surgical specimen. Results One hundred and seventy-two samples from nine breast surgical specimens were evaluated for their fluorescence intensity. Among them, 52 were malignant (30.2%) and 120 were benign (69.8%). The mean TBFR was 3.3 (SD 1.68) in malignant samples and 1.9 (SD 0.97) in benign samples (p = 0.0002). With a TBFR cut-off value of 1.3, the sensitivity, specificity, negative predictive value, false negative rate, and false positive rate of ICG-FI to predict residual tumoral disease in breast surgical samples post-NACT were 94.2%, 31.7%, 92.7%, 5.8%, and 68.3%, respectively. If we restricted our analysis to only patients who achieved pCR, the negative predictive value for ICG-FI was 100%. Conclusions These first observations indicate that ex vivo ICG-FI is sensitive but not sufficiently specific to discriminate between benign breast tissue and malignant residual tissue. Nevertheless, its negative predictive value seems sufficiently accurate to exclude the presence of residual breast tumor tissue on the operative specimen of patients treated by NACT, representing a potential tool to assist pathologists in the assessment of breast surgical specimens.
Breast Journal | 2018
Catalin-Florin Pop; Claudia Stanciu-Pop; Stylianos Drisis; Magali Radermeker; Carine Vandemerckt; D. Noterman; Michel Moreau; Denis Larsimont; Jean-Marie Nogaret; Isabelle Veys
The size and focality of the primary tumor in breast cancer (BC) influence therapeutic decision making. The purpose of this study was to evaluate whether preoperative breast magnetic resonance imaging (MRI) is helpful for the assessment of tumor size and surgical planning in early BC.
Journal De Gynecologie Obstetrique Et Biologie De La Reproduction | 2006
D. Noterman; Catherine Philippson; Dina Hertens; Isabelle Veys; Jean Schobbens; Jean-Marie Nogaret
Journal De Gynecologie Obstetrique Et Biologie De La Reproduction | 2006
D. Noterman; Catherine Philippson; Dina Hertens; Isabelle Veys; Jean Schobbens; Jean-Marie Nogaret
European Journal of Cancer | 2018
P. Catalin Florin; Romain Barbieux; Michel Moreau; D. Noterman; F. De Neubourg; Jean-Marie Nogaret; Gabriel Liberale; Denis Larsimont; Pierre Bourgeois; Isabelle Veys
The Breast | 2011
Catherine Philippson; J.-M. Nogales; Stéphane Simon; C. Vandekerkhove; Dina Hertens; Isabelle Veys; D. Noterman; F. de Neubourg; Denis Larsimont; P. Van Houtte
Radiotherapy and Oncology | 2011
Stéphane Simon; Catherine Philippson; C. Vandekerhove; Jean-Marie Nogaret; Isabelle Veys; D. Noterman; F. de Neubourg; P. Van Houtte